Overall, A‐366 is a novel and highly selective G9a/GLP inhibitor that has not only advanced our understanding of these enzymes in leukemia biology but also holds promise for future therapeutic strategies targeting G9a/GLP‐mediated epigenetic regulation in cancer. This evidence concerns the gene EHMT2 and cancer.